Optical genome and epigenome mapping of clear cell renal cell carcinoma
NAR Cancer · 2025
DOI: 10.1093/narcan/zcaf008 ↗Kurz gefasst
Fachartikel in der Zeitschrift NAR Cancer, 2025. Verfasst von Sapir Margalit und 15 weiteren Autor:innen. Beteiligte Einrichtung: School of Chemistry, Raymond and Beverly Sackler Faculty of Exact Sciences, Tel Aviv University, 6997801 Tel Aviv, Israel. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Epigenome, Chromosome Mapping. Die Arbeit nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NHGRI NIH HHS, European Research Council, consolidator.
Abstract (Originalsprache)
Cancer cells display complex genomic aberrations that include large-scale genetic rearrangements and epigenetic modulation that are not easily captured by short-read sequencing. This study presents a novel approach for simultaneous profiling of long-range genetic and epigenetic changes in matched cancer samples, focusing on clear cell renal cell carcinoma (ccRCC). ccRCC is a common kidney cancer subtype frequently characterized by a 3p deletion and the inactivation of the von Hippel–Lindau (VHL) gene. We performed integrated genetic, cytogenetic, and epigenetic analyses on paired tumor and adjacent nontumorous tissue samples. Optical genome mapping identified genomic aberrations as structural and copy number variations, complementing exome-sequencing findings. Single-molecule methylome and hydroxymethylome mapping revealed a significant global reduction in 5hmC level in both sample pairs, and a correlation between both epigenetic signals and gene expression was observed. The single-molecule epigenetic analysis identified numerous differentially modified regions, some implicated in ccRCC pathogenesis, including the genes VHL, PRCC, and PBRM1. Notably, pathways related to metabolism and cancer development were significantly enriched among these differential regions. This study demonstrates the feasibility of integrating optical genome and epigenome mapping for comprehensive characterization of matched tumor and adjacent tissue, uncovering both established and novel somatic aberrations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Chemistry, Raymond and Beverly Sackler Faculty of Exact Sciences, Tel Aviv University, 6997801 Tel Aviv, Israel.
- Institute of Experimental Botany of the Czech Academy of Sciences, 77900, Olomouc, Czech Republic.
- Institute of Organic Chemistry, RWTH Aachen University, D-52056 Aachen, Germany.
- Pediatric Stem Cell Research Institute, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, 52621 Ramat Gan, Israel.
- Pediatric Nephrology Unit, The Edmond and Lily Safra Children's Hospital, Sheba Medical Center, 52621 Ramat Gan, Israel.
- School of Medicine, Faculty of Medical and Health Sciences, Tel-Aviv University, 6997801 Tel Aviv, Israel.
ORCID-Profile: Zuzana Tulpová, Yuval Ebenstein
Förderung
- NHGRI NIH HHS
- European Research Council
- consolidator
- Israel Science Foundation
- National Human Genome Research Institute
- Ministry of Education and Research
Zitieren
APA
Margalit, S., Tulpová, Z., Michaeli, Y., Zur, T. D., Deek, J., Louzoun-Zada, S., Nifker, G., Grunwald, A., Scher, Y., Schütz, L., Weinhold, E., Gnatek, Y., Omer, D., Dekel, B., Friedman, E., & Ebenstein, Y. (2025). Optical genome and epigenome mapping of clear cell renal cell carcinoma. NAR Cancer. https://doi.org/10.1093/narcan/zcaf008
Vancouver
Margalit S, Tulpová Z, Michaeli Y, Zur TD, Deek J, Louzoun-Zada S, et al. Optical genome and epigenome mapping of clear cell renal cell carcinoma. NAR Cancer. 2025. doi:10.1093/narcan/zcaf008
BibTeX
@article{Margalit2025,
author = {Margalit, Sapir and Tulpová, Zuzana and Michaeli, Yael and Zur, Tahir Detinis and Deek, Jasline and Louzoun-Zada, Sivan and Nifker, Gil and Grunwald, Assaf and Scher, Yuval and Schütz, Leonie and Weinhold, Elmar and Gnatek, Yehudit and Omer, Dorit and Dekel, Benjamin and Friedman, Eitan and Ebenstein, Yuval},
title = {Optical genome and epigenome mapping of clear cell renal cell carcinoma},
journal = {NAR Cancer},
year = {2025},
doi = {10.1093/narcan/zcaf008}
}
EUVIMED